Search
Back 

Research Results

Research Results Press Releases and Announcements

October 4, 2017

Antiangiogenesis Therapy Improves Overall Survival for Patients with Advanced Cervical Carcinoma

Final analysis results of the NRG Oncology/GOG-0240 clinical trial corroborated that the addition of the US Food and Drug Administration (FDA)-approved antiangiogenesis drug bevacizumab to chemotherapy contributed to clinically significant increase in overall survival for patients with advanced cervical cancer. The findings of this National Cancer Institute (NCI)-sponsored study represent a proof-of-concept of the efficacy and tolerability of antiangiogenesis therapy in the treatment of this patient population. These results were published online in The Lancet on July 27, 2017. The study was conducted under the Cooperative Research and Development Agreement between Genentech and NCI for bevacizumab. Read the full press release here.

September 26, 2017

Knowledge-Based Planning Model Aids Clinical Trial Outcomes

The utilization of a knowledge-based planning (KBP) model, developed by researchers at the University of Michigan in collaboration with NRG Oncology, was shown to impact plan quality on the clinical trial NRG Oncology/RTOG 0631. The abstract “Improving Quality and Consistency in Clinical Trials via Knowledge-Based Planning, NRG Oncology RTOG 0631” was presented at the American Society for Radiation Oncology (ASTRO) 59th Annual Meeting September 24-27th in San Diego, California and was the recipient of a “Best of ASTRO” award for 2017. Read the full press release here.

MGMT Promoter Predicts Overall Survival for Patients with Anaplastic Astrocytoma

NRG Oncology trial RTOG 9813 determined that MGMT promoter methylation was an independent predictor of overall survival for patients with anaplastic astrocytoma, a type of malignant brain tumor. The abstract “MGMT Promoter Status Independently Predicts Overall Survival in Anaplastic Astrocytoma in NRG Oncology/RTOG 9813: A Phase III Trial of Radiation Plus Nitrosourea Versus Radiation Plus Temozolomide” was presented at the American Society for Radiation Oncology (ASTRO) 59th Annual Meeting in San Diego, California and was also a recipient of a “Best of ASTRO” award for 2017. Read the full press release here.

September 25, 2017

Phase III trial confirms pelvic radiation as standard of care for high-risk, early-stage endometrial cancer

In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I-II high-risk endometrial cancer were not superior following vaginal cuff brachytherapy plus chemotherapy when compared with pelvic radiation therapy. Risks of pelvic and para-aortic nodal recurrence and frequency of short-term side effects were greater for the brachytherapy-chemotherapy approach. High completion rates for each treatment arm suggest that both therapies are well-tolerated by patients. Findings will be presented today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO). Read full press release here.

Nomograms Developed and Validated for Patients with Squamous Cell Carcinoma of Larynx by NRG Oncology

NRG Oncology researchers have developed and validated nomograms to predict overall survival (OS), locoregional recurrence (LRR), and distant metastasis (DM) for patients receiving definitive chemoradiation for laryngeal squamous cell carcinoma (LSCC). The abstract titled “Development of Laryngeal Cancer Nomograms from Pooled Data of Two Trials of Concurrent Chemoradiation: NRG Oncology RTOG 0129 and RTOG 0522” was presented at the American Society for Radiation Oncology (ASTRO) 59th Annual Meeting September 24-27th in San Diego, California and was selected for a “Best of ASTRO” award for 2017. Read full press release here.

September 24, 2017

Results of NRG Oncology SBRT Comparison Trial for Lung Cancer Patients Consistent after Long-term Follow-up

Long-term follow-up of NRG Oncology trial RTOG 0915 displayed no excess in late-appearing toxicity and similar primary tumor control in both original study arms. The abstract “Long-term follow-up on NRG Oncology/RTOG 0915 (NCCTG N0927): A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients with Stage I Peripheral Non-small Cell Lung Cancer” was presented at the American Society for Radiation Oncology (ASTRO) 59th Annual Meeting in San Diego, California and received a “Best of ASTRO” award for 2017. Read the full press release here.

First Study of Its Kind Depicts Benefits of Brachytherapy for Patients with recurrent Prostate Cancer after EBRT 

A recent midpoint follow-up of the NRG Oncology clinical trial RTOG 0526 determined that late treatment-related grade 3, 4, and 5 gastrointestinal (GI) and genitourinary (GU) adverse events were acceptably low for patients who received salvage brachytherapy for recurrent prostate cancer after prior external beam radiotherapy (EBRT). The results of the abstract “A Prospective Phase II Trial of Trans-perineal Ultrasound-guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy” were presented at the American Society for Radiation Oncology (ASTRO) 59th Annual Meeting in San Diego, California, during the Clinical Trials Session on September 24, 2017.  Read the full press release here.

September 6, 2017

Long-Term Peripheral Neuropathy Associated with Taxane Use in Patients with Early-Stage Breast Cancer

In the secondary analyses of the NRG Oncology’s National Surgical Breast and Bowel Project (NSABP) B-30 trial, the investigators determined that lower-dose docetaxel regimens were associated with lower rates of patient-reported long-term peripheral neuropathy (PN) symptoms in patients treated for early-stage breast cancer. “Long-term Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant Chemotherapy: NRG Oncology/NSABP B-30” was published in the Journal of the National Cancer Institute on August 24, 2017. Read full press release here

August 21, 2017

Nomograms Provide Accurate Prediction of Overal Survival and Progression-Free Survival for Patients with Oropharyngeal Cancer

NRG Oncology researchers recently developed and validated a nomogram that can predict 2-year and 5-year overall survival (OS) and progression-free survival (PFS) for patients with local-regionally advanced oropharyngeal squamous cell carcinoma (OPSCC) treated primarily with radiation-based therapy. This nomogram was developed with data from clinical trials NRG Oncology/RTOG 0129 and 0522. Results were published online in the Journal of Clinical Oncology on August 4, 2017. Read full press release here.

July 25, 2017

Results of NRG-RTOG 0436 Highlight Need for Biomarkers in Treatment of Esophageal Cancer

NRG-RTOG 0436 has determined that adding an epidermal growth factor receptor (EGFR) inhibitor to a chemo-radiation regimen does not improve overall survival for patients with locally advanced esophageal cancer treated in a non-operative manner. These results are reported in “Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients with Esophageal Cancer – The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial,” which was recently published in the Journal of the American Medical Association (JAMA) Oncology. Read the full press release here.

February 2, 2017

Anti-androgen Therapy in Addition to Radiation Therapy Improves Long-term Survival for Men with Recurrent or Persistent Prostate Cancer

NRG Oncology investigators found that daily bicalutamide during and for 24 months after salvage radiation therapy improved long-term survival for men with persistent or recurrent cancer following radical prostatectomy. The results of NRG Oncology’s RTOG 9601, “Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer” will be published in the New England Journal of Medicine on February 2, 2017. Read the full press release here

January 26, 2017

NRG Oncology Researchers Develop Improved Model to Predict Glioblastoma Patients’ Response to Radiation Temozolomide Chemotherapy

A secondary analysis of the clinical trial NRG-RTOG 0525 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients with Newly Diagnosed Glioblastoma or Gliosarcoma was initiated to refine the existing, clinically-based partitioning analysis (RPA) model by incorporating molecular variables. The results of this analysis were published in the Journal of the American Medical Association (JAMA) Oncology on January 12, 2017. Read the full press release here.

December 16, 2016 

NRG-LU001 Reaches Patient Accrual Goal

NRG Oncology clinical trial NRG-LU001 successfully reached its accrual goal of 168 patients. NRG-LU001: Randomized Phase II Trial of Concurrent Chemoradiotherapy with or without Metformin Hydrochloride (HCL) in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) is the first clinical trial that seeks to determine whether metformin added to standard, concurrent chemoradiotherapy can improve progression-free survival (PFS) for patients with locally advanced NSCLC. Read the full press release here.

October 14, 2016

Catching Up with the Cancer Moonshot
-WebMD spoke to NRG Oncology Co-chair, Walter Curran, MD. Read the interview here.

October 6, 2016

Douglas W. Arthur, MD, on Breast Preserving Surgery: Results From NRG Oncology/RTOG 1014

Douglas W. Arthur, MD, of Virginia Commonwealth University, discusses the 3-year efficacy report from NRG-RTOG 1014, a phase II study of repeat breast preserving surgery and 3D conformal partial breast re-irradiation for in-breast recurrence, in an interview with the ASCO Post.

Watch the video on the ASCO Post website.

September 28, 2016

Intensity Modulated Radiation Therapy Associated with Reduction in Patient Reported Xerostomia in Head and Neck Cancer Patients

Radiation therapy is the main treatment modality in the management of head and neck cancer. Due to the close proximity of many important normal structures, radiotherapy can result in severe acute and late toxicities, particularly long-term xerostomia and feeding tube dependency. A pooled analysis of data from NRG Oncology studies RTOG 0129 and 0522 compared intensity-modulated radiotherapy (IMRT) with three-dimensional conformal radiotherapy (3D-CRT) for patients treated for locally advanced head and neck squamous cell carcinoma. The study found that IMRT was associated with significantly reduced xerostomia and feeding tube dependency after treatment, especially in oropharyngeal cancer patients. Read the full article here.

September 27, 2016

IDH and CIC Mutations Provide Prognostic Information for Grade II and III Gliomas

NRG Oncology investigators have identified two biomarkers that are prognostic of overall and progression-free survival for patients with lower-grade gliomas. This combined mutational analysis using specimens from two NRG Oncology clinical trials is the first study to examine the prognostic effects of mutations within IDH1/2, ATRX, CIC, FUBP1 and the TERT promoter using rigorous multivariate analysis (MVA) in a combined cohort of grade II and grade III gliomas with prospectively-collected, well-annotated clinical data. These results were presented at the American Society of Radiation Oncology (ASTRO) Annual Meeting in Boston, Massachusetts, September 27, 2016. Read the full article here.

September 26, 2016

Shortened Radiation Therapy Schedule Effective in Patients with Low-Risk Prostate Cancer

NRG Oncology investigators found delivering higher doses of radiation therapy over 13 fewer days than conventional therapy was safe, more convenient for patients, and was associated with lower costs and similar quality of life outcomes for patients with favorable-risk prostate cancer. NRG-RTOG 0415: A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer comparted standard dose radiation therapy to a radiation therapy schedule that required higher does in fewer treatments to determine if the effects of the treatment were similar in terms of survival and toxicities that effect quality of life. Read the full article here.

Intensity Modulated Pelvic Radiation Therapy Reduces Patient Reported Toxicities

NRG Oncology investigators report better patient-reported quality of life measures for women who received intensity modulated radiation therapy (IMRT) for their pelvic radiation therapy (RT) than those who received standard RT. NRG-RTOG 1203 was designed to assess if the IMRT, by reducing the amount of radiation received by the normal bowel and bladder structure, could decrease side effects for women receiving pelvic radiation. Read the full article here.

The Addition of External Beam Therapy to Brachytherapy Does Not Produce Superior Progression-Free Survival Results for Intermediate Risk Prostate Cancer Patients

NRG Oncology researchers reported that adding external radiation therapy to standard brachytherapy did not improve progression-free survival for men with intermediate-risk prostate cancer. The initial primary endpoint results of NRG-RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate-Risk Prostatic Carcinoma were presented at today’s plenary session of the American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston, Massachusetts. Read the full article here.

September 25, 2016

Stereotactic Body Radiation Therapy Found Safe for Medically Inoperable Patients with Non-Small Cell Lung Cancer

Stereotactic body radiotherapy (SBRT) has been increasingly utilized for medically inoperable early stage non-small-cell lung cancer with patients with centrally located tumors receiving a lower radiation dose that what is prescribed for patients with peripherally located tumors due to normal tissue toxicity concerns. NRG-RTOG 0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients tested the safety of using SBRT at different dose levels for patients with centrally located NSCLC. NRG. Read the full article here.

September 12, 2016

Gynecologic Oncology Group Protocol 240 - Three Years After

Although cytologic screening programs with or without high risk human papillomavirus (HPV) DNA testing have dramatically reduced the incidence and mortality rates due to cervical cancer in developed countries, in the United States there are still over 12,000 new cases and 4,000 deaths attributable to this disease every year. Globally, cervical cancer is the third most common cause of cancer-related mortality in women with over 500,000 new cases and 250,000 deaths annually. Upon successful implementation, cervical cancer vaccination programs are expected to reduce the disease burden further. Read the full article here.

June 7, 2016

NRG RTOG 0617 Shows Survival Correlation for Low versus High Enrolling Institutions for Patients with LA-NSCLC

Philadelphia, PA— Lung cancer is the leading cause of cancer-related death in the United States and is estimated to have contributed to 221,200 new cases and 158,040 deaths in 2015 alone. A secondary analysis of NRG Oncology’s clinical trial RTOG 0617, published in the Journal of the National Cancer Institute, was initiated in an effort to evaluate the effect of institution accrual volume on clinical outcomes among patients receiving chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC). The study showed that patients treated at institutions with higher trial accrual volume on a phase III trial had statistically significant longer overall survival compared with patients treated at low-volume centers. Read full press release here

May 19, 2016

Promising Survival Outcomes from Primary CNS Lymphoma Patients Treated with Rituximab, Chemotherapy, and Radiation

Philadelphia, PA — Primary central nervous system (CNS) lymphoma is an uncommon brain tumor, and premature death results for a high percentage of patients diagnosed with this type of tumor. The Radiation Therapy Oncology Group (RTOG), now conducting research as NRG Oncology, initiated the trial RTOG 0227 (A Phase I and II Study of Induction Chemotherapy with Methotrexate, Rituximab, and Temozolomide, Followed by Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma) to examine the 2-year survival rate in this patient population. The clinical trial results, published online May 10th in the Journal of Clinical Oncology, confirms that the regimen was determined to be safe and highly effective. Read full press release here.

April 7, 2016

The Addition of Chemotherapy to Radiation Therapy Prolongs Survival among Adults with Low-Grade Glial Brain Tumors

Philadelphia, PA—Although grade 2 glial brain tumors (gliomas) constitute only 5 to 10 percent of all brain tumors, progressive neurologic symptoms and premature death result for nearly all patients diagnosed with this type of brain tumor. The Radiation Therapy Oncology Group (RTOG), now conducting research as NRG Oncology, initiated the trial RTOG 9802 (A Phase III Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma) in an effort to improve patient survival. In the April 7 issue of The New England Journal of Medicine, NRG Oncology researchers report the long-term results of this randomized clinical trial, which demonstrate that patients who received radiation therapy (RT) plus a chemotherapy regimen including procarbazine, lomustine (CCNU), and vincristine (PCV) experienced a longer progression-free survival (PFS) and overall survival (OS) than those who received RT alone. Read full press release here.

April 6, 2016

The Treatment of Men With Low-Risk Prostate Cancer Using a Shortened Radiotherapy Schedule Has Similar Efficacy as Treatment With the Longer Conventional Radiotherapy Schedule

Philadelphia, PA—Of the more than 220,000 patients newly diagnosed with prostate cancer in 2015, the vast majority will have had early-stage disease at low risk for recurrence. A clinical trial published online April 4th in the Journal of Clinical Oncology confirms that these patients can be treated with a shortened (or hypofractionated) course of radiotherapy (70 Gy of radiation delivered in 28 fractions over 5.6 weeks) and experience a similar level of cancer control as those treated with a conventional course of radiotherapy (73.8 Gy of radiation delivered in 41 fractions over 8.2 weeks). Coordinated by the Radiation Therapy Oncology Group (RTOG), now conducting research as NRG Oncology, RTOG 0415 analyzed data from 1,092 men diagnosed with low-risk prostate cancer who were randomly assigned to either a conventional schedule lasting more than 8 weeks (542 men) or a hypofractionated schedule (550 men). Read full press release here.

October 21, 2015

Toxicity Data Reported for the Use of SBRT in the Treatment of Patients With Early-Stage and Centrally Located Non-Small Cell Lung Cancer Tumors Show the Treatment is Well Tolerated

SAN ANTONIO—Toxicity results of the phase I/II NRG Oncology/RTOG 0813 trial evaluating the use of stereotactic body radiotherapy (SBRT) for treating patients who are not surgical candidates and have lung cancer tumors that are located centrally in the chest were reported today at the 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO). The trial’s principal investigator, Andrea Bezjak, M.D., M.Sc., F.R.C.P.C., a professor of radiation oncology at the University of Toronto in Ontario, Canada, presented data showing that overall the treatment was well tolerated and that the highest dose level allowed by the protocol (12 Gy delivered x  5 fractions over 1.5−2 weeks, total dose 60 Gy) was reached. The trial is the first to implement a phase I/II continuous reassessment design employed to collect toxicity and efficacy data safely and expeditiously in the evaluation of dose-escalating SBRT treatment. Read full press release here.

BRCA1 Expression in Glioblastoma Multiforme Tumors Predicts Patient Survival

Results of a study conducted by the Radiation Therapy Oncology Group (RTOG), now conducting research as NRG Oncology, are the first to show that breast cancer type 1 susceptibility gene (BRCA1) protein expression is an important predictive biomarker of overall survival in patients with glioblastoma multiforme (GBM) tumors. The study reported today at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO) investigated the expression and prognostic significance of four molecular biomarkers for their potential role in the formation and growth of GBM tumors. “Among the four biomarkers assessed, only BRCA1 protein expression had a statistically significant correlation with overall survival,” says the study’s principal investigator, Maria Vasilakopoulou, M.D., Ph.D., a medical oncologist and clinical researcher at the Pitié-Salpêtrière Hospital, in Paris, France, who carried out the research in the laboratory of David Rimm, M.D., Ph.D, a professor of pathology and medical oncology at Yale University. Specifically, patients with low tumor BRCA1 protein expression survived longer in comparison with patients with high expression of this protein, with median survival times of 18.9 versus 4.8 months, respectively.  Read full press release here.

Toxicity Data Reported for the Use of SBRT in the Treatment of Patients With Early-Stage and  Centrally Located Non-Small Cell Lung Cancer Tumors Show the Treatment is Well Tolerated

Toxicity results of the phase I/II NRG Oncology/RTOG 0813 trial evaluating the use of stereotactic body radiotherapy (SBRT) for treating patients who are not surgical candidates and have lung cancer tumors that are located centrally in the chest were reported today at the 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO). The trial’s principal investigator, Andrea Bezjak, M.D., M.Sc., F.R.C.P.C., a professor of radiation oncology at the University of Toronto in Ontario, Canada, presented data showing that overall the treatment was well tolerated and that the highest dose level allowed by the protocol (12 Gy delivered x  5 fractions over 1.5−2 weeks, total dose 60 Gy) was reached. The trial is the first to implement a phase I/II continuous reassessment design employed to collect toxicity and efficacy data safely and expeditiously in the evaluation of dose-escalating SBRT treatment. Read full press release here .

October 19, 2015

The Treatment of Men With Low-Risk Prostate Cancer Using a Shortened Radiotherapy Schedule Has Similar Efficacy as Treatment With the Longer Conventional Radiotherapy Schedule

SAN ANTONIO—Of the more than 220,000 patients expected to be newly diagnosed with prostate cancer in 2015, the vast majority will have early-stage disease at low risk for recurrence. Clinical trial results presented today at the plenary session of the 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO) confirm that these patients can be treated with a shortened (or hypofractionated) course of radiotherapy (70 Gy of radiation delivered in 28 fractions over 5.6 weeks) and experience the same level of cancer control as those treated with a conventional course of radiotherapy (73.8 Gy of radiation delivered in 41 fractions over 8.2 weeks). Conducted by the Radiation Therapy Oncology Group (RTOG), now conducting research as NRG Oncology, RTOG 0415  analyzed data from 1,092 patients diagnosed with low-risk prostate cancer who were randomized to either the hypofractionated schedule arm (550 patients) or the conventional schedule arm (542 patients).  Read full presss release here

The Randomized NRG Oncology RTOG 9601 Protocol Reports That Men With Prostate Cancer Who Have a PSA Recurrence Following Radical Prostatectomy Have Improved Survival With the Addition to Salvage Radiotherapy of a Long-term Course of Antiandrogen Therapy Compared With Salvage Radiotherapy Alone

SAN ANTONIO—It is well established that a rising serum prostate-specific antigen (PSA) level is an indication of cancer progression in men diagnosed with prostate cancer and treated with radical prostatectomy (RP). For these patients, adding 24 months of anti-androgen therapy (AAT) during and after salvage radiotherapy (RT) improves overall survival statistically compared with treating them with salvage RT alone, according to the long-term results of a clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), now conducting research as NRG Oncology. The RTOG 9601 study results presented today at the plenary session of the 57th Annual  Meeting of the American Society for Radiation Oncology (ASTRO) also reveal that the addition of ATT to salvage RT reduces prostate cancer death and the development of metastatic prostate cancer without increasing radiation toxicity. Read full press release here.

June 1, 2015

Postmenopausal Women Treated for Ductal Carcinoma In Situ (DCIS) Breast Cancer Gain Significant Benefit From Treatment With Anastrazole Compared With Tamoxifen 

Chicago, Ill., June 1, 2015—Primary results of NSABP B-35, a phase III randomized, double-blind clinical trial conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP), now conducting research as NRG Oncology, show that anastrozole, as compared with tamoxifen, provides a significant improvement in the time that postmenopausal patients with estrogen receptor-positive ductal carcinoma in situ (DCIS) remain breast cancer-free (the period from randomization to any breast cancer recurrence). At a mean follow-up time of 8.6 years, this result was seen in women primarily younger than age 60 years. The NSABP B-35 trial principal investigator, Richard Margolese, MD, a professor in the departments of surgery and oncology at McGill University in Montreal, Quebec, reported the primary study results today at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago during the morning’s breast cancer session.

“Although tamoxifen therapy has been effective in patients with DCIS, some women receiving this drug still experience relapse or suffer side effects,” says Margolese. “This led us to search for more effective and less toxic agents to control the stimulation and growth of precancerous and cancerous cells in the breast. The long-term follow-up of NSABP B-35 provides solid evidence of anastrozole’s superior cancer control, especially in women younger than 60 years.” Anastrozole, an aromatase inhibitor, works by reducing the amount of circulating estrogen. Tamoxifen, a selective estrogen receptor modulator, works by blocking the action of estrogen receptors. Read full release here.

Trial Results Evaluating the Addition of Bevacizumab to Paclitaxel/Carboplatin Chemotherapy Support Further Investigation of Anti-angiogenesis Targeting Agents in Endometrial Cancer

Chicago, Ill., June 1, 2015—The Gynecologic Oncology Group (GOG), now conducting research as NRG Oncology, carried out a three-arm, phase II randomized trial evaluating initial treatment for advanced or recurrent endometrial cancer with paclitaxel and/or carboplatin chemotherapy that incorporated one of three novel agents: bevacizumab, temsirolimus, or ixabepilone. Initial results of the GOG 86P trial were reported today at the 2015 American Society for Clinical Oncology Annual Meeting. Lead investigator and presenter Carol Aghajanian, MD, PhD, chair of the NRG Oncology Developmental Therapeutics Committee and chief of the Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York, reported that, when compared with the paclitaxel/carboplatin arm of the GOG 209 study serving as the historical control reference, no significant difference in progression-free survival was found in any of the three arms (Arm 1: paclitaxel, carboplatin, and bevacizumab; Arm 2: paclitaxel, carboplatin, and temsirolimus; and Arm 3: carboplatin, ixabepilone, and bevacizumab). However, at the 36-month follow-up, investigators observed a statistically significant increase in overall survival in Arm 1 relative only to the historical control.

“The three agents evaluated in this study have all shown promise in the treatment of endometrial cancer; however, their role in combination with the paclitaxel/carboplatin chemotherapy in the initial treatment of endometrial cancer has been unknown,” says Aghajanian. “These results support further evaluation of anti-angiogenesis targeting in endometrial cancer. Specifically, the true meaning of the survival benefit in this study needs to be evaluated in trials with a concurrent control arm.” Read full press release here.

May 30, 2015

Patients with Prostate Cancer at High Risk for Metastasis Live Longer When Chemotherapy is Added to the Standard Treatment Regimen of Radiotherapy and Hormonal Therapy

Chicago, Ill, May 31, 2015—The initial results of a randomized phase III trial reported today at the 2015 American Society of Clinical Oncology Annual Meeting show that the addition of docetaxel chemotherapy (and prednisone) to standard treatment extends significantly the lives of men diagnosed with high-risk prostate cancer that has not spread outside the pelvic region. Risk was determined as the combination of Gleason score (a rating of how aggressive cancer cells appear microscopically), pretreatment prostate-specific androgen (PSA) level, and tumor stage. The study analysis of RTOG 0521, initially conducted by the Radiation Therapy Oncology Group (RTOG), now conducting research as NRG Oncology, included 562 patients enrolled at sites across the United States and Canada, and in Australia. Patients were randomized to receive either the standard treatment (radiotherapy [RT] plus 2-year hormonal [androgen suppression] therapy) or the experimental treatment (RT, 2-year hormonal therapy plus docetaxel chemotherapy beginning 28 days after the completion  of RT).  

“Adjuvant chemotherapy had been shown to have an effective role in other high-incidence cancers, such as lung, breast, and colorectal. This led us to test the hypothesis that treating patients who, at initial diagnosis, are at the greatest risk of dying from prostate cancer with adjuvant chemotherapy early on would result in a survival benefit,” says lead abstract author and presenter Howard M. Sandler, MD, MS, FASTRO, the principal investigator of the RTOG 0521 trial, chair of the NRG Oncology Genitourinary Cancer Committee, and chair of radiation oncology at Cedars-Sinai Medical Center in Los Angeles.  Read the full release here.

April 8, 2015

Patient-Reported Outcomes Analysis of High-Dose 3D-CRT vs IMRT for Prostate Cancer

The results of a preliminary patient-reported outcomes analysis of high-dose 3D-CRT vs IMRT for intermediate-risk prostate cancer published online before print on April 2 in the journal Cancer show no differences in outcomes between the two modalities. 

Long-Term Survival Benefit of Intraperitoneal vs Intravenous Chemotherapy for Advanced Ovarian Cancer

The survival benefit of intraperitoneal vs intravenous chemotherapy in women with advanced ovarian cancer extends beyond 10 years, according to the results of a retrospective analysis of the GOG 114 and GOG 172 clinical trial data published online before print on March 23 in the Journal of Clinical Oncology.  

Read full announcement

February 9, 2015

Image-guided Radiotherapy Reduces Long-term Treatment Side Effects

Results of the clinical trial RTOG 0630 establish a new standard of care for the treatment of soft tissue sarcoma. Read press release

January 27, 2015

Higher-Dose RT Results in Inferior Survival in Patients With Stage III Lung Cancer

Results of a randomized phase III clinical trial demonstrated that treatment with higher-dose (74 Gy) radiotherapy (RT) compared with standard-dose (60 Gy) RT, and the addition of cetuximab to concurrent chemoradiotherapy, did not extend the lives of patients with inoperable, stage III non-small cell lung cancer. Read press release

December 29, 2014

Men with Intermediate-Risk Prostate Cancer Have Excellent Outcomes and Fewer Treatment Side Effects with a Short Course of Hormonal Therapy Prior to Radiotherapy

Men with prostate cancer who are at intermediate risk for cancer recurrence after initial treatment are best served with an 8-week course of androgen suppression therapy (AST), followed by radiotherapy (RT) with an additional 8 weeks of AST, according to results of the RTOG 9910 randomized clinical trial published online December 22 in the Journal of Clinical Oncology. Read press release

December 15, 2014

Treatment Setting for Patients with Locally Advanced Head and Neck Cancer Impacts Survival and Cancer Progression

Patients with locally advanced head and neck cancer (HNC) treated at medical centers with historically low patient enrollment in HNC clinical trials are more likely to die from their disease compared to those treated at centers with high patient enrollment in HNC clinical trials Read press release

November 10, 2014

Intensity-Modulated Radiotherapy Technique that Avoids Radiation Dose to the Hippocampus Safeguards Patients' Memory

Use of an intensity-modulated radiotherapy technique that avoids radiation dose to the hippocampus during whole-brain radiotherapy safeguards patients’ memory, according to results of a clinical trial published online on October 27, 2014 in the Journal of Clinical Oncology. Read press release

October 24, 2014

Tumor Human Papillomavirus Status Is a Strong Predictor of Survival for Patients With Oropharyngeal Cancer Progressing After Initial Treatment

In an article published this week in the Journal of Clinical Oncology, data from 181 patients with HPV-positive oropharyngeal cancer (OPC) showed that patients with HPV-positive OPC had significantly improved survival rates compared with patients with HPV-negative OPC (2.6 vs. 0.8 years, respectively, at a median of 4 years after disease progression).
Read press release

October 6, 2014

An analysis of 356 tumor specimens shows p16 expression is not a reliable indicator of human papillomavirus (HPV) in oral cavity, hypopharynx, and larynx cancers

Research published online in the Journal of Clinical Oncology reported results of an investigation that pooled head and neck tumor specimens for analysis that were collected as part of three clinical trials conducted by the Radiation Therapy Oncology Group, which is now conducting research as NRG Oncology.
Read press release

September 22, 2014

Patients with Head and Neck Cancers Do Not Benefit from the Addition of Cetuximab to Standard Chemoradiotherapy

The addition of cetuximab to treatment with cisplatin and radiotherapy did not improve the outcome of patients with locally advanced (non-metastatic) head and neck cancer (HNC) according to results of the phase III, RTOG 0522 clinical trial published in the Journal of Clinical Oncology.
Read press release

September 17, 2014

From ASTRO

Promising Results for Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer 

Two NRG Oncology presentations at the American Society for Radiation Oncology Annual Meeting show promising results for the treatment of muscle-invasive bladder cancer.

Read press release

September 15, 2014

From ASTRO

Long-Term Results of the RTOG 0236 Stereotactic Body Radiotherapy Trial Confirm the Modality’s Important Role in the Treatment of Early-Stage, Medically Inoperable Non-Small Cell Lung Cancer

Results of the 5-year follow-up on patients who participated in the RTOG 0236 clinical trial show good cancer control of the stereotactic body radiotherapy (SBRT)-treated area and no increase in the rate of late-appearing treatment side effects compared with results reported at 3 years of follow up.
Read press release

Higher-Dose Radiation Shown to Control Prostate Cancer Effectively in Patients At Intermediate Risk for Cancer Recurrence

The initial results of the randomized, phase III RTOG 0126 trial demonstrate that higher-dose (79.2 Gy) radiotherapy (RT) vs. standard-dose (70.2 Gy) RT resulted in fewer patients experiencing prostate-specific antigen (PSA) failures, prostate cancer progression, metastases, or initial treatment failure.
Read press release

September 14, 2014

From ASTRO

Treatment with Radiotherapy, Androgen Suppression Therapy, and Docetaxel Improves Cancer Control 

Patients at high risk for prostate cancer recurrence after radical prostatectomy and adjuvant radiotherapy realize significantly improved cancer control with the addition of systemic androgen suppression therapy and docetaxel chemotherapy as compared with historical controls according to results of the Radiation Therapy Oncology Group (RTOG) 0621 clinical trial presented the at the American Society for Radiation Oncology 56th Annual Meeting, in San Francisco.
Read press release 

June 1, 2014

From ASCO

Patients with Head and Neck Cancer Who Have the KRAS-variant Genetic Mutation Live Longer When Treated with Cetuximab and Radiotherapy

Results of a study conducted by Radiation Therapy Oncology Group (RTOG) investigators found that patients with locally advanced head and neck squamous cell cancer (HNSCC), who have an inherited KRAS-variant gene mutation, significantly benefit from a treatment regimen that includes the drug cetuximab. 
Read press release

April 3, 2014

Men Receiving Radiotherapy for Prostate Cancer Found Not to Benefit from Daily Dosing of Tadalafil (Cialis®) for Prevention of Treatment-related Erectile Dysfunction

Men diagnosed with early-stage prostate cancer who received daily doses of tadalafil to prevent radiotherapy (RT) treatment-related erectile dysfunction (ED) gained no significant sexual function benefit compared with those who received a placebo, according to results of a clinical trial published in the April 2, 2014 issue of JAMA.
Read press release

To view a short video about the trial results produced by Emory University go to
RTOG 0831 Trial Results.

February 19, 2014

Bevacizumab as First-Line Treatment for Newly Diagnosed Glioblastoma Brain Tumors Found Not to Extend Patients’ Lives

Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival,. Results appear in the February 20, 2014 issue of “New England Journal of Medicine.”
Read press release


 










 

Copyright 2017 by NRG Oncology